Revolution Medicines has randomized the first patient in RASolute 304, a global, open-label Phase 3 study testing daraxonrasib as adjuvant therapy in resected pancreatic ductal adenocarcinoma following perioperative chemotherapy. The trial plans to enroll approximately 500 patients with RAS-mutant tumors and will compare daraxonrasib to observation. Disease-free survival is the primary endpoint, with overall survival, safety, and tolerability as key secondaries.
The move extends daraxonrasib beyond advanced disease into a maintenance-style setting where no targeted standards currently exist. By positioning a RAS(ON) multi-selective inhibitor against observation after surgery and chemotherapy, the company is seeking to create a new post-chemo intervention point in a cancer type where recurrence rates remain stubbornly high. RASolute 304 is one of four ongoing Phase 3 trials for daraxonrasib, including three in pancreatic cancer and one in RAS-mutant NSCLC, signaling a coordinated push to validate the asset across lines of therapy and tumor contexts.
Strategically, the adjuvant trial is an expansion play that leverages the drug’s mutation-agnostic reach across common KRAS variants (G12X, G13X, Q61X). In pancreatic cancer, where RAS mutations are near-universal, this approach minimizes friction in biomarker screening and maximizes the theoretical addressable population compared to allele-selective competitors. It also attempts to convert early clinical signals from later-line settings into a durable benefit where tolerability thresholds are stricter and margins for toxicity are narrower. The choice of disease-free survival as the primary endpoint aligns with precedents in other solid tumors but will face scrutiny in pancreatic cancer, where regulators and clinicians often prioritize overall survival given the disease’s aggressive biology and the lack of validated surrogate endpoints.
For sites, the operational demands are nontrivial. Enrollment requires coordination across surgical and medical oncology teams to identify eligible patients who have cleared perioperative chemotherapy and are within a tight post-resection window. While genotyping is unlikely to be a barrier given the prevalence of RAS mutations in PDAC, standardized surveillance to assess DFS events and manage open-label treatment may add workflow complexity. The observation control mitigates comparator heterogeneity but requires consistent follow-up and objective event adjudication to address potential bias in an unblinded design. CROs will need a broad geographic reach to hit the sample size, given that only a minority of PDAC patients undergo resection and an even smaller subset complete perioperative chemotherapy and remain eligible for adjuvant intervention.
Sponsors with allele-selective KRAS programs face a near-term differentiation challenge. A positive readout here could establish a foothold for a mutation-agnostic RAS inhibitor in a setting with limited competition and few constraints on mutation subtyping. Conversely, any tolerability issues common to pan-RAS inhibition could erode the risk-benefit calculus in adjuvant use, particularly if discontinuations dilute DFS gains. Regulators will also weigh the appropriateness of DFS for approval and the magnitude of benefit required to shift post-chemo surveillance to active maintenance.
The next set of signals to watch: enrollment velocity, interim monitoring plans, and how the company sequences readouts across its other Phase 3 PDAC studies to build a coherent value proposition spanning first-line, later-line, and adjuvant settings. Subgroup analyses by RAS mutation class and prior chemotherapy regimen will be critical for adoption, as will any exploratory biomarkers that help identify patients most likely to benefit. The central question remains whether a multi-selective RAS(ON) inhibitor can deliver tolerable, durable disease control in the adjuvant setting—strong enough to change a surveillance default without compromising quality of life or long-term outcomes.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
